Back to top
more

Merus N.V. (MRUS)

(Delayed Data from NSDQ)

$18.00 USD

18.00
45,371

0.00 (0.00%)

Updated Aug 22, 2019 04:00 PM ET

After-Market: $17.94 -0.06 (-0.33%) 6:38 PM ET

Add to portfolio

3-Hold     3    

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1
2
3
4
5
S&P
Strong Buy
Buy
Hold
Sell
Strong Sell
500
24.58%
17.73%
9.37%
4.95%
1.76%
10.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

F Value | F Growth | B Momentum | F VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Zacks News

Zacks Equity Research

Merus N.V. (MRUS) Reports Q2 Loss, Misses Revenue Estimates

Merus N.V. (MRUS) delivered earnings and revenue surprises of -5.56% and -27.29%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

MRUS

Zacks Equity Research

Acorda (ACOR) Q2 Earnings and Revenues Surpass Estimates

Acorda (ACOR) posts narrower-than-expected loss while revenues top estimates in the second quarter. Inbrija delivers a solid start with sales rising sequentially.

ACOR MRUS RGEN MYL

Zacks Equity Research

Moving Average Crossover Alert: Merus

Merus is looking like an interesting pick from a technical perspective.

MRUS

Zacks Equity Research

NuCana Initiates Dosing in Phase I Study for Solid Tumors

NuCana (NCNA) doses the first patient in a phase I study on NUC-7738, which is being evaluated for the treatment of advanced solid tumors.

LLY RGEN MRUS NCNA

Zacks Equity Research

Will Merus N.V. (MRUS) Report Negative Q2 Earnings? What You Should Know

Merus N.V. (MRUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MRUS

Zacks Equity Research

Moleculin Files New Patents for Cancer Candidate Annamycin

Moleculin (MBRX) petitions for new patents to cover annamycin, currently being developed for treating patients with relapsed or refractory acute myeloid leukemia. Shares rise.

INVA MRUS KDMN MBRX

Zacks Equity Research

Moving Average Crossover Alert: Merus

Merus N.V. (MRUS) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

MRUS

Zacks Equity Research

Inovio Ends Enrollment in Vulvar Dysplasia Study on VGX-3100

Inovio (INO) closes enrollment in the phase II study, evaluating VGX-3100 for the treatment of HPV-related vulvar dysplasia.

INO MRUS RGEN QGEN

Zacks Equity Research

Nabriva Gets EMA Acceptance for Pneumonia Drug Lefamulin

The EMA endorses Nabriva Therapeutics' (NBRV) marketing application for both the intravenous and oral formulations of lefamulin to treat adult patients with community-acquired pneumonia.

ACOR MRUS RGEN NBRV

Zacks Equity Research

Vertex's (VRTX) Symdeko Gets FDA Nod for Use in Children

Vertex's (VRTX) Symdeko gets FDA approval to treat underlying cause of cystic fibrosis in children aged 6-11 years with certain mutations in the CFTR gene.

VRTX MRUS ACOR ANIK

Zacks Equity Research

Akari (AKTX) Eye Candidate Proves Safety in Early-Stage Study

Akari (AKTX) presents favorable safety data from part A of an early-stage study on nomacopan for treating moderate to severe atopic keratoconjunctivitis. Shares appreciate.

ACOR RGEN MRUS AKTX

Zacks Equity Research

Merus N.V. (MRUS) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Merus N.V. (MRUS).

MRUS

Zacks Equity Research

Intrexon Up on Striking 100M Cannabinoid Deal With Surterra

Intrexon (XON) inks a $100-million worth exclusive licensing deal with Surterra to produce cannabinoid in a reliable and cost-effective fashion, using its own yeast fermentation process. Shares climb.

RGEN MRUS ACOR XON

Zacks Equity Research

Athenex Rallies on Positive Early Data on Psoriasis Candidate

Athenex (ATNX) shares rise on encouraging preliminary data from an early-stage study on KX2-391, currently under development for treating patients with psoriasis.

ACOR RGEN MRUS ATNX

Zacks Equity Research

Reata's (RETA) Kidney Candidate Gets Orphan Drug Status

The FDA bestows an orphan drug designation on Reata Pharmaceuticals' (RETA) candidate, bardoxolone, for treating patients with autosomal dominant polycystic kidney disease.

ACOR RETA RGEN MRUS

Zacks Equity Research

Agios' Tibsovo Meets Endpoint in Cholangiocarcinoma Study

Agios' (AGIO) Tibsovo achieves the primary goal in a late-stage development that examined it for the previously treated IDH1 mutant cholangiocarcinoma. Shares rise in after-hours trading.

AGIO GILD CELG MRUS

Zacks Equity Research

Mallinckrodt Ends Enrollment in Phase III for Terlipressin

Mallinckrodt (MNK) concludes enrollment in the phase III study on terlipressin, currently under development for treating adult patients with Hepatorenal Syndrome Type 1.

RGEN GILD MRUS MNK

Zacks Equity Research

Tilray (TLRY) to Report Q1 Earnings: What's in the Cards?

Investors will focus on pipeline progress and updates, when Tilray (TLRY) reports first-quarter 2019 results.

NVS MRUS ADVM TLRY

Zacks Equity Research

Tilray (TLRY) to Report Q1 Earnings: What's in the Cards?

Investors will focus on pipeline progress and updates, when Tilray (TLRY) reports first-quarter 2019 results.

NVS ADVM MRUS TLRY

Zacks Equity Research

Evoke Pharma (EVOK) to Post Q1 Earnings: What's in Store?

During Evoke Pharma's (EVOK) Q1 conference call, investor focus will be on its progress and issues related to the NDA submission for Gimoti to treat diabetic gastroparesis.

ADVM MRUS RGEN EVOK

Zacks Equity Research

Agios (AGIO) Earnings and Revenues Surpass Estimates in Q1

Agios (AGIO) benefits from earnings as well as revenue beat in first-quarter 2019. However, Tibsovo sales fall sequentially, pulling the stock down.

AGIO PDLI CELG MRUS

Zacks Equity Research

Acorda (ACOR) Earnings and Revenues Beat Estimates in Q1

Acorda's (ACOR) shares rise on earnings and revenue beat in Q1. Inbrija registers first sales figure following its launch in the reported quarter.

PDLI MRUS ACOR MYL

Zacks Equity Research

Vertex (VRTX) Q1 Earnings and Revenues Surpass Estimates

Vertex (VRTX) beats on both earnings and sales in Q1 with demand for its newest CF drug, Symdeko, rising high.

VRTX PDLI MRUS CRSP

Zacks Equity Research

BioMarin (BMRN) Shares Down Despite Q1 Earnings & Sales Beat

BioMarin's (BMRN) earnings and revenues surpass estimates in the first quarter.

SNY PDLI BMRN MRUS

Zacks Equity Research

Kamada to Begin Phase III Study for Inhaled AAT Product in 2H

Kamada (KMDA) wins the FDA acceptance for the path forward regarding its inhaled Alpha-1-Antitrypsin product, currently under development for treating Alpha-1 Antitrypsin Deficiency.

MRUS PDLI KMDA TAK